fashion -WSS

fashion

author：focus 2025-09-06 03:58:13 - browse：974

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： As health system earnings go up, health insurance stocks go down

hotspot

knowledge

WSS

Brain MRIs reveal impact of 'toxic stress' on Black children

EU climate chief is concerned over the expansion of the coal industry in China

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

New air purifier tech could be key to improving indoor air quality

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Jerome Adams on the need for new antivirals for Covid

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

DIEP, the 'gold standard' of breast reconstruction, is under threat

As billionaires fund anti

In age of alternative facts, a scholarly course on calling out crap

NASA releases new images of 'fingerprint

Wildfire smoke exposes gaps in outdoor worker protections

A timeline of the missing Titanic tourist submersible

hotspot

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Russians and Belarusians back at Wimbledon as war in Ukraine continues

Most antidepressants don't work on kids, teens, study finds

Noem? Reynolds? A very early look at the Republican 'veepstakes'

HHS's proposed rule does nothing to address the climate crisis

1 dead, 9 hurt in July 4th fireworks explosion

leisure time

hotspot

knowledge

focus